Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Open accessAbstract
The intestinal microbiota influence neurodevelopment, modulate behavior, and contribute to neurological disorders. However, a functional link between gut bacteria and neurodegenerative diseases remains unexplored. Synucleinopathies are characterized by aggregation of the protein α-synuclein (αSyn), often resulting in motor dysfunction as exemplified by Parkinson's disease (PD). Using mice that overexpress αSyn, we report herein that gut microbiota are required for motor deficits, microglia activation, and αSyn pathology. Antibiotic treatment ameliorates, while microbial re-colonization promotes, pathophysiology in adult animals, suggesting that postnatal signaling between the gut and the brain modulates disease. Indeed, oral administration of specific microbial metabolites to germ-free mice promotes neuroinflammation and motor symptoms. Remarkably, colonization of αSyn-overexpressing mice with microbiota from PD-affected patients enhances physical impairments compared to microbiota transplants from healthy human donors. These findings reveal that gut bacteria regulate movement disorders in mice and suggest that alterations in the human microbiome represent a risk factor for PD.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The increased level of inflammatory cytokines may be caused by disturbance of the gut microbiota, which may also disrupt the gut barrier.
“The increased level of inflammatory cytokines may be caused by disturbance of the gut microbiota, which may also disrupt the gut barrier. 241”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [241]
The microglia results (p. 5) report higher pro-inflammatory cytokines in mice with gut microbes than in germ-free mice, supporting the proposed link between microbiota and cytokines in this PD model. The passages found do not say that microbiota disturbance disrupts the gut barrier; a search for intestinal permeability and barrier effects found no supporting passage. (LLM, conf=0.86)
Experimental — accuracy not yet measuredWhen α-synuclein over-expressing transgenic mice were raised in a germ-free environment they rarely developed the cardinal features of PD such as rest tremor, bradykinesia, and rigidity.
“For example, one study showed that when α-synuclein over-expressing transgenic mice were raised in a germ-free environment they rarely developed the cardinal features of PD such as rest tremor, bradykinesia, and rigidity.”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [92]
In “Gut Microbes Promote Motor and GI Dysfunction” (p. 4), germ-free α-synuclein-overexpressing mice had reduced motor-task deficits, often performing similarly to wild-type mice. The study did not establish that they rarely developed rest tremor, bradykinesia, or rigidity: it measured beam traversal, pole descent, adhesive removal, and hindlimb clasping instead, and reported a remaining limb-strength defect. (LLM, conf=0.88)
Experimental — accuracy not yet measuredWhen these mice were either colonized with feces from wild-type mice or orally fed bacterial metabolites like short chain fatty acids (SCFAs) without colonization, they developed a PD-like phenotype.
“When these mice were either colonized with feces from wild-type mice or orally fed bacterial metabolites like short chain fatty acids (SCFAs) without colonization, they developed a PD-like phenotype [92].”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [92]
The Postnatal Microbial Signals section (p. 6) reports that colonizing germ-free mice with microbiota from wild-type mice restored motor dysfunction in the alpha-synuclein-overexpressing mice. The SCFA sections (pp. 6–7) report motor deficits after SCFA treatment while the mice remained sterile. However, the Methods (p. 16) specify that the colonizing material was cecal contents, not feces; the effects were specific to the genetically susceptible mice. (LLM, conf=0.86)
Experimental — accuracy not yet measuredFMT from PD patient donors worsens disease progression, suggesting the presence of specific disease-promoting microbes.
“In contrast, FMT from PD patient donors worsens disease progression suggesting the presence of specific disease-promoting microbes (169).”
From The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication (2020) · cites this paper as [169]
The Results (pp. 9–10) report that microbiota from PD donors increased motor impairment in genetically susceptible ASO mice compared with microbiota from healthy donors. The Discussion (p. 11) suggests distinct PD-associated microbes may contribute to symptoms, but says whether specific microbes play a role remains unknown. The study shows worsened motor deficits in a mouse model, not worsening disease progression in PD patients. (LLM, conf=0.86)
Experimental — accuracy not yet measuredThese mice showed changes in SCFAs, with lower concentrations of acetate and higher concentrations of propionate and butyrate.
“In addition, these mice showed changes in SCFAs, with lower concentrations of acetate and higher concentrations of propionate and butyrate, substantiating that the alteration of gut microbiota is a crucial risk factor for Parkinson's disease.50”
From The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options (2021) · cites this paper as [50]
In “Dysbiosis of the PD Microbiome” (p. 9), mice receiving PD donor-derived microbiota had lower acetate concentrations than mice receiving healthy-control microbiota. The paper reports higher *relative abundances* of propionate and butyrate, not higher absolute concentrations, so that part of the claim overstates the finding. (LLM, conf=0.87)
Experimental — accuracy not yet measured
The alteration of gut microbiota is a crucial risk factor for Parkinson's disease.
“In addition, these mice showed changes in SCFAs, with lower concentrations of acetate and higher concentrations of propionate and butyrate, substantiating that the alteration of gut microbiota is a crucial risk factor for Parkinson's disease.50”
From The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options (2021) · cites this paper as [50]
The Dysbiosis of the PD Microbiome section (p. 9) reports lower acetate and higher relative propionate and butyrate in mice receiving microbiota from PD donors. The Discussion (p. 10) says these mouse findings suggest that dysbiosis can influence disease outcomes in genetically susceptible mice, but treats their relevance to human PD as a possible extrapolation—not an established crucial risk factor. (LLM, conf=0.88)
Experimental — accuracy not yet measuredPrior work indicated that the biodiversity and composition of the gut microbiome are linked to various aspects of mouse cognition and behavior.
“Prior work7,46,47, indicated that the biodiversity and composition of the gut microbiome are linked to various aspects of mouse cognition and behavior.”
From Integrated analysis of behavioral, epigenetic, and gut microbiome analyses in AppNL-G-F, AppNL-F, and wild type mice (2021) · cites this paper as [7]
The Introduction (p. 4) reports prior work linking gut microbiota to mouse anxiety, hyperactivity, and cognition. The Results (pp. 9–10) link differences in microbial communities to motor performance in a Parkinson’s mouse model. Our copy does not establish a link between microbiome biodiversity specifically and mouse cognition or behavior. (LLM, conf=0.83)
Experimental — accuracy not yet measuredThe presence of gut microbes is necessary to elicit pathophysiological alterations in a mouse model of αSyn overexpression, because elimination of the gut microbiota with antibiotics ameliorated the condition.
“However, the presence of gut microbes is necessary to elicit pathophysiological alterations in a mouse model of αSyn overexpression, because elimination of the gut microbiota with antibiotics ameliorated the condition (169).”
From The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication (2020) · cites this paper as [169]
Increased SCFA levels have been implicated in the pathophysiology of Parkinson's disease in mice.
“For instance, increased SCFA levels have been implicated in the pathophysiology of Parkinson's disease in mice (Sampson et al., 2016).”
From The Microbiota-Gut-Brain Axis (2019) · cites this paper as Sampson et al., 2016
In mice colonized by the faeces of patients with Parkinson's disease, the abundance of Proteus sp., Bilophila sp. and Roseburia sp. increased, with a decrease in Lachnospiracae, Rikenellae, Peptostreptococacae and Butyricicoccus sp.
“Intriguingly, the abundance of some gut microbiota increased in mice that were colonized by the faeces of patients with Parkinson's disease, including Proteus sp., Bilophila sp. and Roseburia sp., with a decrease in the Lachnospiracae, Rikenellae, Peptostreptococacae and Butyricicoccus sp.50”
From The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options (2021) · cites this paper as [50]
In mice colonized by the gut microbiota of patients with Parkinson's disease, high expression of α-synuclein increased motor dysfunction.
“In animal experiments, Sampson et al.50 found that the high expression of a-synuclein in mice that were colonized by the gut microbiota of patients with Parkinson's disease increased motor dysfunction.50”
From The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options (2021) · cites this paper as Sampson et al.50
The gut microbiome might be a contributor to AD in humans and may play an important role in AD models as well.
“These data suggest that as seen in Parkinson’s disease (PD) and PD models7, the gut microbiome might be a contributor to AD in humans and may play an important role in AD models as well.”
From Integrated analysis of behavioral, epigenetic, and gut microbiome analyses in AppNL-G-F, AppNL-F, and wild type mice (2021) · cites this paper as [7]
Metabolomic biomarkers such as reduced docosahexaenoic acid (DHA) and elevated homocysteine have demonstrated clinical utility.
“Despite variability introduced by diet and comorbid conditions, metabolomic biomarkers such as reduced docosahexaenoic acid (DHA) and elevated homocysteine have demonstrated clinical utility133,194, 195, 196, 197, 198, 199.”
From Artificial intelligence-driven multi-omics approaches in Alzheimer's disease: Progress, challenges, and future directions (2025) · cites this paper as [195]
The Figure S6 caption (p. 25) discusses microbial metabolic pathways and short-chain fatty acids in mice, not clinical biomarkers. Searches for DHA, homocysteine, and clinical utility found no passage in our copy addressing the claimed biomarkers or their clinical use. (LLM, conf=0.76)
Experimental — accuracy not yet measuredStudies on animal models have provided compelling evidence that the altered gut microbiome drives neurodegenerative disease pathogenesis, primarily through the modulation of microglial functions and activation.
“Moreover, studies on animal models have provided compelling evidence that the altered gut microbiome drives neurodegenerative disease pathogenesis, primarily through the modulation of microglial functions and activation.54–57”
From Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases (2024) · cites this paper as [55]
FMT from PD patients to GF ASO mice restored the main disease features, including α-synuclein-mediated motor dysfunction.
“Importantly, FMT from PD patients to GF ASO mice restored the main disease features, including α-synuclein-mediated motor dysfunction.55”
From Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases (2024) · cites this paper as [55]
SCFA supplementation in GF ASO mice induces microglial activation, α-synuclein accumulation, and motor dysfunction.
“Of note, SCFA supplementation in GF ASO mice induced microglial activation, α-synuclein accumulation and motor dysfunction.55”
From Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases (2024) · cites this paper as [55]
Changes in the F/B ratio are associated with various disorders, such as irritable bowel syndrome and inflammatory bowel disease, as well as with neurodegenerative diseases, such as PD, AD, and ALS.
“Changes in the F/B ratio have been found to be associated with various disorders, such as irritable bowel syndrome and inflammatory bowel disease (97), as well as with neurodegenerative diseases, such as PD, AD, and ALS (98).”
From Modulation of the gut–brain axis via the gut microbiota: a new era in treatment of amyotrophic lateral sclerosis (2023) · cites this paper as [98]
Intestinal microbes are closely related to neurological diseases such as AD, PD and ALS.
“Intestinal microbes are closely related to neurological diseases such as AD, PD and ALS.”
From Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer’s disease and Parkinson’s disease (2020) · cites this paper as Sampson et al. 2016
Disturbed intestinal flora can affect neurogenesis, development, neurotransmission and neuroimmunity, ultimately affecting the pathogenesis and progress of NDD.
“In addition, disturbed intestinal flora can affect neurogenesis, development, neurotransmission and neuroimmunity (Sampson et al. 2016), which ultimately affect the pathogenesis and progress of NDD.”
From Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer’s disease and Parkinson’s disease (2020) · cites this paper as Sampson et al. 2016
In the faecal samples of PD patients, the abundance of Escherichia-Shigella, Proteus, and Enterococcus is increased, and the abundance of Blautia and Ruminococcus is decreased.
“Similarly, the abundance of Escherichia-Shigella, Proteus, and Enterococcus was increased, and the abundance of Blautia and Ruminococcus was decreased in the faecal samples of PD patients (Sampson et al. 2016).”
From Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer’s disease and Parkinson’s disease (2020) · cites this paper as Sampson et al. 2016
There is a strong connection between intestinal microbiota and nervous diseases.
“Till now, a strong connection between intestinal microbiota and nervous diseases is evidenced, and the drug GV-971 has been conditionally approved by China’s State Drug Administration for AD treatment.”
From Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer’s disease and Parkinson’s disease (2020) · cites this paper as Sampson et al. 2016
FMT from PD patients to mice leads to aggravation of motor deficits via activation of microglia.
“Sampson et al. demonstrated that fecal microbiota transplantation (FMT) from PD patients to mice led to the aggravation of motor deficits via the activation of microglia”
From Healthy Human Fecal Microbiota Transplantation into Mice Attenuates MPTP-Induced Neurotoxicity <i>via</i> AMPK/SOD2 Pathway (2023) · cites this paper as [17]
Mice given fecal microbiota from PD patients exhibited even worse loss of TH+ neurons compared to MPTP-treated mice.
“Of note, the mice given fecal microbiota from PD patients exhibited even worse loss of TH+ neurons, corroborating previous findings [17].”
From Healthy Human Fecal Microbiota Transplantation into Mice Attenuates MPTP-Induced Neurotoxicity <i>via</i> AMPK/SOD2 Pathway (2023) · cites this paper as [17]
FMT from PD patients can significantly worsen motor dysfunction in α-synuclein-overexpressing (ASO) mice compared to genotype-matched recipient mice receiving FMT from healthy human controls.
“FMT from PD patients can significantly worsen motor dysfunction in α-synuclein-overexpressing (ASO) mice compared to genotype-matched recipient mice receiving FMT from healthy human controls [17]”
From Healthy Human Fecal Microbiota Transplantation into Mice Attenuates MPTP-Induced Neurotoxicity <i>via</i> AMPK/SOD2 Pathway (2023) · cites this paper as [17]
Dysbiosis is observed in several neurological conditions in which microglial dysfunction is thought to be a contributing factor to disease development, including ASD and PD.
“Second, dysbiosis is observed in several neurological conditions in which microglial dysfunction is thought to be a contributing factor to disease development, including ASD and PD (Table 1; Hsiao et al., 2013; Sampson et al., 2016).”
From Microbiome–microglia connections via the gut–brain axis (2019) · cites this paper as Sampson et al., 2016
Studies in germ-free mice overexpressing human α-synuclein provide support for the notion that the microbiota may drive the pathogenesis of Parkinson's disease.
“Support for the notion that the microbiota may drive the pathogenesis of PD was provided by studies in GF mice that overexpress human α-synuclein.”
From Microbiome–microglia connections via the gut–brain axis (2019) · cites this paper as Sampson et al., 2016
Feeding germ-free transgenic mice overexpressing human α-synuclein a mixture of three SCFAs up-regulated microglial activation and induced motor deficits similar to those observed in colonized animals.
“Feeding these GF transgenic mice a mixture of three SCFAs up-regulated microglial activation and induced motor deficits similar to those observed in colonized animals (Sampson et al., 2016).”
From Microbiome–microglia connections via the gut–brain axis (2019) · cites this paper as Sampson et al., 2016
Germ-free mice overexpressing human α-synuclein display reduced motor deficits, GI dysfunction, and microglial activation compared with mice with an intact gut microbiota.
“These mice display reduced motor deficits, GI dysfunction, and microglial activation when compared with mice with an intact gut microbiota (Sampson et al., 2016).”
From Microbiome–microglia connections via the gut–brain axis (2019) · cites this paper as Sampson et al., 2016
The gut microbiota, along with genetic predisposition, may be required for the onset and/or progression of Parkinson's disease.
“This observation suggests that the gut microbiota, along with genetic predisposition, may be required for disease onset and/or progression.”
From Microbiome–microglia connections via the gut–brain axis (2019) · cites this paper as Sampson et al., 2016
Microbiota-derived SCFAs are crucial for α-synuclein-mediated neuroinflammation, glial cell hyperactivation, and motor symptoms.
“Sampson et al. showed that microbiota-derived SCFAs are crucial for α-synuclein-mediated neuroinflammation, glial cell hyperactivation, and motor symptoms [10].”
From Neuroprotective Effects of Bifidobacterium breve CCFM1067 in MPTP-Induced Mouse Models of Parkinson’s Disease (2022) · cites this paper as [10]
PD pathogenesis may be affected by alterations in the gut microbiota.
“recent studies have demonstrated that PD pathogenesis may be affected by alterations in the gut microbiota [5,6,7].”
From Neuroprotective Effects of Sodium Butyrate by Restoring Gut Microbiota and Inhibiting TLR4 Signaling in Mice with MPTP-Induced Parkinson’s Disease (2023) · cites this paper as [5]
There is an increase in proinflammatory microorganisms in the intestinal microbiota of PD patients.
“There is an increase in proinflammatory microorganisms in the intestinal microbiota of PD patients [41]”
From Neuroprotective Effect of Ceftriaxone on MPTP‐Induced Parkinson’s Disease Mouse Model by Regulating Inflammation and Intestinal Microbiota (2021) · cites this paper as [41]
Changing the endotoxin-producing bacterial species can affect Parkinson's disease in patients and mouse models.
“changing the endotoxin-producing bacterial species can affect the disease in patients and mouse models.”
From The endotoxin hypothesis of neurodegeneration (2019) · cites this paper as [95]
The gut microbiome affects motor symptoms in an α-synuclein mouse model of Parkinson's disease, such that eliminating gut bacteria prevents motor deficits, while introducing the gut microbiome from PD patients exacerbates pathology.
“And the gut microbiome affects motor symptoms in an α-synuclein mouse model of PD, such that eliminating gut bacteria prevents motor deficits, while introducing the gut microbiome from PD patients exacerbates pathology [95].”
From The endotoxin hypothesis of neurodegeneration (2019) · cites this paper as [95]
In a PD model, antibiotics improve PD pathology, while oral specific microbial metabolites increase neuroinflammation and motor symptoms.
“In a PD model, antibiotic treatment ameliorates PD pathology, whereas oral administration of specific microbial metabolites promotes neuroinflammation and motor symptoms150.”
From Microglia in neurodegeneration (2018) · cites this paper as [150]
α-Synuclein-dependent activation of microglia may be linked to changes in the microbiome in animal models and patients.
“it has been reported that α-synuclein-dependent activation of microglia may be linked to changes in the microbiome in both animal models and patients162.”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [162]
In Parkinson's disease, dysbiosis followed by gastrointestinal symptoms and gut discomfort far precedes the onset of motor dysfunctions and is linked to neuroinflammation and alterations in dopamine, serotonin, and kynurenine metabolism through the gut-brain axis.
“Concerning PD, dysbiosis followed by GI symptoms and gut discomfort far precedes the onset of motor dysfunctions and it is linked to neuroinflammation, as well as to alterations in dopamine, serotonin, and kynurenine metabolism through the gut-brain axis [40,41,42,43,44,45,46]”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [40]
Transfer of fecal matter from human PD patients to α-synuclein overexpressing mice substantially worsened their physical symptoms compared with mice receiving feces from healthy human donors.
“Early evidence came in 2016 from the work of Sampson et al., who first reported that the transfer of fecal matter from human PD patients to α-synuclein overexpressing mice substantially worsened their physical symptoms in comparison with mice receiving feces from healthy human donors [40].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [40]
Consistent preclinical studies and a handful of human case reports have shown that FMT might reduce motor and non-motor symptoms, as well as constipation, in PD at least in the short term.
“Concerning PD, consistent preclinical studies and a handful of human case reports have shown that FMT might be exploited to reduce motor and non-motor symptoms, as well as constipation, at least in the short term [40,465,469,470,471,472,473,474,475,476,477] (Table 4).”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [40]
Mice overexpressing α-synuclein given antibiotic treatment or raised under germ-free conditions displayed improved motor functions and reduced amount of α-synuclein deposits.
“Mice overexpressing α-synuclein given antibiotic treatment or raised under GF conditions displayed improved motor functions and reduced amount of α-synuclein deposits.”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [404]
FMT from patients with Parkinson's disease to mice overexpressing α-synuclein aggravated motor function problems more profoundly than gut bacteria derived from healthy subjects, suggesting that manifestation of disease symptoms is related to the shift in gut microbiota.
“FMT from patients with Parkinson's disease to mice overexpressing α-synuclein aggravated the problems in motor functions more profoundly than gut bacteria derived from healthy subjects, which suggested that the manifestation of disease symptoms is related to the shift in gut microbiota [404].”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [404]
Recent studies have shown dramatic changes in the GM of patients with Alzheimer's disease, Parkinson's disease, multiple sclerosis, and schizophrenia.
“Furthermore, recent studies have shown dramatic changes in the GM of patients with Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and schizophrenia (73–77).”
From Signalling cognition: The gut microbiota and hypothalamic-pituitary-adrenal axis (2023) · cites this paper as [75]
FMT from Parkinson's disease-affected patients enhances Parkinsonism compared to FMT from healthy human donors in α-synuclein mice.
“Oral administration of SCFAs to germ-free α-synuclein mice promoted neuroinflammation and motor dysfunction, and FMT with Parkinson’s disease-affected patients enhanced the Parkinsonism compared to FMT from healthy human donors.”
From Signalling cognition: The gut microbiota and hypothalamic-pituitary-adrenal axis (2023) · cites this paper as [75]
Oral administration of SCFAs to germ-free α-synuclein mice promotes neuroinflammation and motor dysfunction.
“Oral administration of SCFAs to germ-free α-synuclein mice promoted neuroinflammation and motor dysfunction, and FMT with Parkinson’s disease-affected patients enhanced the Parkinsonism compared to FMT from healthy human donors.”
From Signalling cognition: The gut microbiota and hypothalamic-pituitary-adrenal axis (2023) · cites this paper as [75]
In an α-synuclein-overexpressing mouse model of Parkinsonism, MGB axis signaling is required for motor deficits, microglia activation, and synucleinopathies.
“In a mouse model that overexpresses the protein α-synuclein, resulting in Parkinsonism, Sampson et al. were able to show that MGB axis signaling is required for motor deficits, microglia activation, and synucleinopathies (75).”
From Signalling cognition: The gut microbiota and hypothalamic-pituitary-adrenal axis (2023) · cites this paper as [75]
The microbiota composition differs significantly between healthy controls and patients affected by neurodegenerative disorders such as multiple sclerosis, Alzheimer's and Parkinson's diseases, and neuropsychiatric disorders.
“The microbiota composition differs significantly between healthy controls and patients affected by neurodegenerative disorders (such as multiple sclerosis (MS), Alzheimer’s (AD) and Parkinson’s (PD) diseases) (20, 22, 23, 32, 111–115), and neuropsychiatric disorders (NPS) (30), like major depressive and mood disorders.”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [111]
GF mice colonized with microbiota from PD patients display physical impairments compared to GF mice colonized with microbiota from healthy human donors.
“GF mice colonized with microbiota from PD patients display physical impairments compared to GF mice colonized with microbiota from healthy human donors (111).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [111]
Differences in microbiome profile, SCFA amount, and motor dysfunctions (increase in propionate and butyrate) were transferred and maintained in vivo in GF mice receiving PD patient-derived feces.
“The differences in the microbiome profile, in SCFAs amount, and motor dysfunctions (increase in propionate and butyrate) were transferred and maintained in vivo too (111).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [111]
In germ-free mice, administration of an SCFA mixture resulted in microglia activation and motor deficits, hallmark symptoms of Parkinson's disease.
“Likewise, in GF mice the administration of an SCFA mixture resulted in microglia activation and motor deficits (369), hallmark symptoms of Parkinson's disease”
From Diet and the Microbiota–Gut–Brain Axis: Sowing the Seeds of Good Mental Health (2021) · cites this paper as [369]
Animal studies have shown that intestinally derived lipopolysaccharides can increase anxiety-like behavior in mice.
“Second, animal studies have shown effects of the gut microbiota on neurodevelopment, suggesting that intestinally derived lipopolysaccharides can increase anxiety-like behavior in mice (69–71).”
From Association Between Gut Microbiota and Autism Spectrum Disorder: A Systematic Review and Meta-Analysis (2019) · cites this paper as [70]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887 · see citing works
Self-citationPredictive functional profiling of microbial communities using 16S rRNA marker gene sequences
Langille, M. G. I., Zaneveld, J., Caporaso, J. G., McDonald, D., Knights, D., Reyes, J. A., Clemente, J. C., Burkepile, D. E., Vega Thurber, R. L., Knight, R., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2676 · Cited by 9,116 · see citing works
Self-citationUniFrac: a New Phylogenetic Method for Comparing Microbial Communities
Lozupone, C., & Knight, R. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.12.8228-8235.2005 · Cited by 8,227 · see citing works
Self-citationSmith, P. M., Howitt, M. R., Panikov, N., Michaud, M., Gallini, C. A., Bohlooly-Y, M., Glickman, J. N., & Garrett, W. S. (2013) · Science · doi:10.1126/science.1241165 · Cited by 5,413 · see citing works
McDonald, D. T., Price, M. N., Goodrich, J. K., Nawrocki, E. P., DeSantis, T. Z., Probst, A. J., Andersen, G. L., Knight, R. D., & Hugenholtz, P. (2011) · The ISME Journal · doi:10.1038/ismej.2011.139 · Cited by 5,010 · see citing works
Self-citationInteractions Between the Microbiota and the Immune System
Hooper, L. V., Littman, D. R., & Macpherson, A. J. (2012) · Science · doi:10.1126/science.1223490 · Cited by 4,173 · see citing works
Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis
Yano, J. M., Yu, K., Donaldson, G. P., Shastri, G. G., Ann, P., Ma, L., Nagler, C. R., Ismagilov, R. F., Mazmanian, S. K., & Hsiao, E. Y. (2015) · Cell · doi:10.1016/j.cell.2015.02.047 · Cited by 3,614 · see citing works
Self-citationHost microbiota constantly control maturation and function of microglia in the CNS
Erny, D., Hrabě de Angelis, A. L., Jaitin, D., Wieghofer, P., Staszewski, O., David, E., Keren-Shaul, H., Mahlakoiv, T., Jakobshagen, K., Buch, T., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.4030 · Cited by 3,569 · see citing works
Gut microbiota, metabolites and host immunity
Rooks, M. G., & Garrett, W. S. (2016) · Nature reviews. Immunology · doi:10.1038/nri.2016.42 · Cited by 3,409 · see citing works
Ecological and Evolutionary Forces Shaping Microbial Diversity in the Human Intestine
Ley, R. E., Peterson, D. A., & Gordon, J. I. (2006) · Cell · doi:10.1016/j.cell.2006.02.017 · Cited by 3,358 · see citing works
Normal gut microbiota modulates brain development and behavior
Heijtz, R. D., Wang, S., Anuar, F., Qian, Y., Björkholm, B., Samuelsson, A., Hibberd, M. L., Forssberg, H., & Pettersson, S. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1010529108 · Cited by 3,228 · see citing works
SortMeRNA: fast and accurate filtering of ribosomal RNAs in metatranscriptomic data
Kopylova, E., Noé, L., & Touzet, H. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts611 · Cited by 3,051 · see citing works
Sudo, N., Chida, Y., Aiba, Y., Sonoda, J., Oyama, N., Yu, X., Kubo, C., & Koga, Y. (2004) · The Journal of Physiology · doi:10.1113/jphysiol.2004.063388 · Cited by 2,735 · see citing works
Luk, K. C., Kehm, V., Carroll, J., Zhang, B., O’Brien, P., Trojanowski, J. Q., & Lee, V. M.-Y. (2012) · Science · doi:10.1126/science.1227157 · Cited by 2,563 · see citing works
The gut microbiota influences blood-brain barrier permeability in mice
Braniste, V., Al-Asmakh, M., Kowal, C., Anuar, F., Abbaspour, A., Tóth, M., Korecka, A., Bakocevic, N., Ng, L. G., Kundu, P., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009759 · Cited by 2,530 · see citing works
Walters, W. A., Hyde, E. R., Berg-Lyons, D., Ackermann, G. L., Humphrey, G. C., Parada, A. E., Gilbert, J. A., Jansson, J. K., Caporaso, J. G., Fuhrman, J. A., et al. (2015) · mSystems · doi:10.1128/msystems.00009-15 · Cited by 2,202 · see citing works
Self-citationGut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968 · see citing works
Analysis of composition of microbiomes: a novel method for studying microbial composition
Mandal, S., Van Treuren, W., White, R. A., Eggesbø, M., Knight, R., & Peddada, S. D. (2015) · Microbial Ecology in Health & Disease · doi:10.3402/mehd.v26.27663 · Cited by 1,942 · see citing works
Self-citationInternational Parkinson's Disease Genomics Consortium (IPDGC), Nalls, M. A., Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI), 23andMe, GenePD, NeuroGenetics Research Consortium (NGRC), Hussman Institute of Human Genomics (HIHG), Investigator, T. A. J. D., (CHARGE), C. F. H. A. A. R. I. G. E., North American Brain Expression Consortium (NABEC), et al. (2014) · Nature Genetics · doi:10.1038/ng.3043 · Cited by 1,895 · see citing works
Clarke, G., Grenham, S., Scully, P., Fitzgerald, P., Moloney, R. D., Shanahan, F., Dinan, T. G., & Cryan, J. F. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.77 · Cited by 1,893 · see citing works
Bercik, P., Denou, E., Collins, J., Jackson, W., Lu, J., Jury, J., Deng, Y., Blennerhassett, P., Macri, J., McCoy, K. D., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.04.052 · Cited by 1,748 · see citing works
Braak, H., R�b, U., Gai, W. P., & Del Tredici, K. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-002-0808-2 · Cited by 1,683 · see citing works
The central nervous system and the gut microbiome
Sharon, G., Sampson, T. R., Geschwind, D. H., & Mazmanian, S. K. (2016) · Cell · doi:10.1016/j.cell.2016.10.027 · Cited by 1,513 · see citing works
Self-citationSignals from the gut microbiota to distant organs in physiology and disease
Schroeder, B. O., & Bäckhed, F. (2016) · Nature Medicine · doi:10.1038/nm.4185 · Cited by 1,409 · see citing works
Neufeld, K. M., Kang, N., Bienenstock, J., & Foster, J. A. (2011) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2010.01620.x · Cited by 1,392 · see citing works
Colonic bacterial composition in Parkinson's disease
Keshavarzian, A., Green, S. J., Engen, P. A., Voigt, R. M., Naqib, A., Forsyth, C. B., Mutlu, E., & Shannon, K. M. (2015) · Movement Disorders · doi:10.1002/mds.26307 · Cited by 1,281 · see citing works
Self-citationEMPeror: a tool for visualizing high-throughput microbial community data
Vázquez‐Baeza, Y., Pirrung, M., Gonzalez, A., & Knight, R. D. (2013) · GigaScience · doi:10.1186/2047-217x-2-16 · Cited by 1,272 · see citing works
Self-citationMicroglia development follows a stepwise program to regulate brain homeostasis
Matcovitch-Natan, O., Winter, D. R., Giladi, A., Vargas Aguilar, S., Spinrad, A., Sarrazin, S., Ben-Yehuda, H., David, E., Zelada González, F., Perrin, P., et al. (2016) · Science · doi:10.1126/science.aad8670 · Cited by 1,180 · see citing works
Unger, M. M., Spiegel, J., Dillmann, K.-U., Grundmann, D., Philippeit, H., Bürmann, J., Faßbender, K., Schwiertz, A., & Schäfer, K.-H. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.08.019 · Cited by 1,159 · see citing works
Mogi, M., Harada, M., Riederer, P., Narabayashi, H., Fujita, K., & Nagatsu, T. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90746-3 · Cited by 986 · see citing works
Kumar, D. K. V., Choi, S. H., Washicosky, K. J., Eimer, W. A., Tucker, S., Ghofrani, J., Lefkowitz, A., McColl, G., Goldstein, L. E., Tanzi, R. E., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf1059 · Cited by 971 · see citing works
Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats
Holmqvist, S., Chutna, O., Bousset, L., Aldrin-Kirk, P., Li, W., Björklund, T., Wang, Z.-Y., Roybon, L., Melki, R., & Li, J.-Y. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1343-6 · Cited by 925 · see citing works
The Earth Microbiome project: successes and aspirations
Gilbert, J. A., Jansson, J. K., & Knight, R. D. (2014) · BMC Biology · doi:10.1186/s12915-014-0069-1 · Cited by 879 · see citing works
Self-citationKim, C., Ho, D.-H., Suk, J.-E., You, S., Michael, S., Kang, J., Joong Lee, S., Masliah, E., Hwang, D., Lee, H.-J., et al. (2013) · Nature Communications · doi:10.1038/ncomms2534 · Cited by 856 · see citing works
Mogi, M., Harada, M., Kondo, T., Riederer, P., Inagaki, H., Minami, M., & Nagatsu, T. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90508-8 · Cited by 855 · see citing works
Vagotomy and subsequent risk of <scp>P</scp> arkinson's disease
Svensson, E., Horváth‐Puhó, E., Thomsen, R. W., Djurhuus, J. C., Pedersen, L., Borghammer, P., & Sørensen, H. T. (2015) · Annals of Neurology · doi:10.1002/ana.24448 · Cited by 806 · see citing works
Spreading of pathology in neurodegenerative diseases: a focus on human studies
Brettschneider, J., Tredici, K. D., Lee, V. M.-Y., & Trojanowski, J. Q. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3887 · Cited by 790 · see citing works
Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism
Prusiner, S. B., Woerman, A. L., Mordes, D. A., Watts, J. C., Rampersaud, R., Berry, D. B., Patel, S. S., Oehler, A., Lowe, J. K., Kravitz, S. N., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1514475112 · Cited by 679 · see citing works
Minter, M. R., Zhang, C., Leone, V., Ringus, D. L., Zhang, X., Oyler-Castrillo, P., Musch, M. W., Liao, F., Ward, J. F., Holtzman, D. M., et al. (2016) · Scientific Reports · doi:10.1038/srep30028 · Cited by 655 · see citing works
Regulation of prefrontal cortex myelination by the microbiota
Hoban, A. E., Stilling, R. M., Ryan, F. J., Shanahan, F., Dinan, T. G., Claesson, M. J., Clarke, G., & Cryan, J. F. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.42 · Cited by 635 · see citing works
Colonic inflammation in Parkinson's disease
Devos, D., Lebouvier, T., Lardeux, B., Biraud, M., Rouaud, T., Pouclet, H., Coron, E., Bruley des Varannes, S., Naveilhan, P., Nguyen, J.-M., et al. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.09.007 · Cited by 627 · see citing works
α-Synuclein Membrane Interactions and Lipid Specificity
Jo, E., McLaurin, J., Yip, C. M., George‐Hyslop, P. S., & Fraser, P. E. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004345200 · Cited by 602 · see citing works
Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson's disease
Hasegawa, S., Goto, S., Tsuji, H., Okuno, T., Asahara, T., Nomoto, K., Shibata, A., Fujisawa, Y., Minato, T., Okamoto, A., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0142164 · Cited by 523 · see citing works
Molecular mechanisms of L-DOPA-induced dyskinesia
Jenner, P. G. (2008) · Nature reviews. Neuroscience · doi:10.1038/nrn2471 · Cited by 522 · see citing works
Rockenstein, E., Mallory, M., Hashimoto, M., Song, D., Shults, C. W., Lang, I., & Masliah, E. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10231 · Cited by 502 · see citing works
Parkinson-associated risk variant in distal enhancer of α-synuclein modulates target gene expression
Soldner, F., Stelzer, Y., Shivalila, C., Abraham, B. J., Latourelle, J. C., Barrasa, M. I., Goldmann, J. E., Myers, R. H., Young, R. A., & Jaenisch, R. (2016) · Nature · doi:10.1038/nature17939 · Cited by 496 · see citing works
Early and Progressive Sensorimotor Anomalies in Mice Overexpressing Wild-Type Human α-Synuclein
Fleming, S. M., Salcedo, J. D., Fernagut, P., Rockenstein, E. M., Masliah, E., Levine, M. S., & Chesselet, M. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.3080-04.2004 · Cited by 477 · see citing works
Self-citationMöhle, L., Mattei, D., Heimesaat, M. M., Bereswill, S., Fischer, A., Alutis, M., French, T., Hambardzumyan, D., Matzinger, P., Dunay, I. R., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.074 · Cited by 470 · see citing works
Is alpha-synuclein in the colon a biomarker for premotor Parkinson’s disease? Evidence from 3 cases
Shannon, K. M., Keshavarzian, A., Dodiya, H. B., Jakate, S., & Kordower, J. H. (2012) · Movement Disorders · doi:10.1002/mds.25020 · Cited by 464 · see citing works
Self-citationSubstantial Production of Dopamine in the Human Gastrointestinal Tract
Eisenhofer, G., Åneman, A., Friberg, P., Hooper, D., Fåndriks, L., Lonroth, H., Hunyady, B., & Mezey, E. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.11.4339 · Cited by 394 · see citing works
A critical evaluation of the Braak staging scheme for Parkinson's disease
Burke, R. E., Dauer, W. T., & Vonsattel, J. P. (2008) · Annals of Neurology · doi:10.1002/ana.21541 · Cited by 377 · see citing works
Bacterial Neuroactive Compounds Produced by Psychobiotics
Wall, R., Cryan, J. F., Ross, R. P., Fitzgerald, G. F., Dinan, T. G., & Stanton, C. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-0897-4_10 · Cited by 362 · see citing works
Gao, H.-M., Zhang, F., Zhou, H., Kam, W., Wilson, B., & Hong, J.-S. (2011) · Environmental Health Perspectives · doi:10.1289/ehp.1003013 · Cited by 355 · cited 1× · see citing works
“Intriguingly, an inflammatory environment is known to enhance aSyn aggregation, which may further activate microglia upon contact and promote a feed-forward cascade that leads to additional aSyn aggregation and propagation and progression of disease (Gao et al., 2011).”
Microbial Succession and Flavor Production in the Fermented Dairy Beverage Kefir
Walsh, A. M., Crispie, F., Kilcawley, K. N., O’Sullivan, Ó., O’Sullivan, M. G., Claesson, M. J., & Cotter, P. D. (2016) · mSystems · doi:10.1128/msystems.00052-16 · Cited by 352 · see citing works
A Progressive Mouse Model of Parkinson’s Disease: The Thy1-aSyn (“Line 61”) Mice
Chesselet, M.-F., Richter, F., Zhu, C., Magen, I., Watson, M. B., & Subramaniam, S. R. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0104-2 · Cited by 346 · see citing works
Mitchell, R. W., On, N. H., Del Bigio, M. R., Miller, D. W., & Hatch, G. M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07245.x · Cited by 337 · see citing works
The Role of Innate and Adaptive Immunity in Parkinson's Disease
Kannarkat, G. T., Boss, J. M., & Tansey, M. G. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130250 · Cited by 324 · see citing works
Altered brain-gut axis in autism: comorbidity or causative mechanisms
Mayer, E. A., Padua, D., & Tillisch, K. (2014) · BioEssays · doi:10.1002/bies.201400075 · Cited by 304 · see citing works
Patient-reported autonomic symptoms in Parkinson disease
Verbaan, D., Marinus, J., Jeukens‐Visser, M., van Rooden, S. M., Stiggelbout, A. M., & van Hilten, J. J. (2007) · Neurology · doi:10.1212/01.wnl.0000266593.50534.e8 · Cited by 283 · see citing works
The impact of gut microbiota on brain and behaviour
Dinan, T. G., & Cryan, J. F. (2015) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000221 · Cited by 267 · see citing works
Therapeutic strategies for human amyloid diseases
Sacchettini, J. C., & Kelly, J. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd769 · Cited by 259 · see citing works
Sánchez-Guajardo, V., Barnum, C. J., Tansey, M. G., & Romero‐Ramos, M. (2013) · ASN NEURO · doi:10.1042/an20120066 · Cited by 237 · see citing works
Of Pesticides and Men: a California Story of Genes and Environment in Parkinson’s Disease
Ritz, B. R., Paul, K. C., & Bronstein, J. M. (2016) · Current Environmental Health Reports · doi:10.1007/s40572-016-0083-2 · Cited by 153 · see citing works
Sex-Specific Effects of Organophosphate Diazinon on the Gut Microbiome and Its Metabolic Functions
Gao, B., Bian, X., Mahbub, R., & Lü, K. (2016) · Environmental Health Perspectives · doi:10.1289/ehp202 · Cited by 125 · see citing works
Metabolic tinkering by the gut microbiome
Selkrig, J., Wong, P., Zhang, X., & Pettersson, S. (2014) · Gut Microbes · doi:10.4161/gmic.28681 · Cited by 116 · see citing works
Wang, L., Magen, I., Yuan, P. Q., Subramaniam, S., Richter, F., Chesselet, M. ‐., & Taché, Y. (2012) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2012.01974.x · Cited by 115 · see citing works
Self-citationCleynen, I., Vazeille, E., Artieda, M., Verspaget, H. W., Szczypiorska, M., Bringer, M.-A., Lakatos, P. L., Seibold, F., Parnell, K. S., Weersma, R. K., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-303205 · Cited by 99 · see citing works
Genes associated with Parkinson's disease: regulation of autophagy and beyond
Beilina, A. G., & Cookson, M. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13266 · Cited by 93 · see citing works
Chorell, E., Andersson, E. K., Evans, M. L., Jain, N., Götheson, A., Ådén, J., Chapman, M. R., Almqvist, F., & Wittung-Stafshede, P. E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140194 · Cited by 88 · see citing works
Self-citationKohman, R. A., Bhattacharya, T. K., Kilby, C. N., Bucko, P. J., & Rhodes, J. S. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.12.032 · Cited by 79 · see citing works
A not entirely benign procedure: progression of Parkinson’s disease
Tredici, K. D., & Braak, H. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0355-5 · Cited by 67 · see citing works
Combination therapies: The next logical Step for the treatment of synucleinopathies?
Valera, E., & Masliah, E. (2015) · Movement Disorders · doi:10.1002/mds.26428 · Cited by 62 · see citing works
Clinical and biochemical correlates of insoluble α-synuclein in dementia with Lewy bodies
Klucken, J., Ingelsson, M., Shin, Y., Irizarry, M. C., Hedley‐Whyte, E. T., Frosch, M. P., Growdon, J. H., McLean, P. J., & Hyman, B. T. (2006) · Acta Neuropathologica · doi:10.1007/s00401-005-0027-7 · Cited by 60 · see citing works
Zhang, J., Saur, T., Duke, A. N., Grant, S. G. N., Platt, D. M., Rowlett, J. K., Ole Isacson, A., & Yao, W. (2014) · Journal of Neurogenetics · doi:10.3109/01677063.2014.892486 · Cited by 55 · see citing works
Four types of B ifidobacteria trigger autophagy response in intestinal epithelial cells
Lin, R., Jiang, Y., Zhao, X. Y., Guan, Y., Qian, W., Fu, X. C., Ren, H. Y., & Hou, X. H. (2014) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12179 · Cited by 33 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- Smith, P.M., Howitt, M.R., Panikov, N., Michaud, M., Gallini, C.A., Bohlooly-Y, M., Glickman, J.N., and Garrett, W.S. (2013). The microbial metabolites, shortchain fatty acids, regulate colonic Treg cell homeostasis. Science 341 , 569-573. http://refhub.elsevier.com/S0092-8674(1631590-2/sref62)
Cited by
Sorted by citations
Cryan, J. F., O'Riordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S., Boehme, M., Codagnone, M. G., Cussotto, S., Fulling, C., Golubeva, A. V., et al. (2019) · Physiological Reviews · doi:10.1152/physrev.00018.2018 · Cited by 5,286 · see citing works
Bloem, B. R., Okun, M. S., & Klein, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00218-x · Cited by 3,920 · see citing works
The role of short-chain fatty acids in microbiota–gut–brain communication
Dalile, B., Van Oudenhove, L., Vervliet, B., & Verbeke, K. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0157-3 · Cited by 3,357 · see citing works
The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication
Silva, Y. P., Bernardi, A., & Frozza, R. L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00025 · Cited by 3,043 · see citing works
“In contrast, FMT from PD patient donors worsens disease progression suggesting the presence of specific diseasepromoting microbes (169).”
BackgroundInfluentialThe gut microbiota–brain axis in behaviour and brain disorders
Morais, L. H., Schreiber, H. L., & Mazmanian, S. K. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00460-0 · Cited by 2,149 · see citing works
Self-citationDysbiosis and the immune system
Levy, M., Kolodziejczyk, A. A., Thaiss, C. A., & Elinav, E. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.7 · Cited by 1,769 · see citing works
Microglia in neurodegeneration
Hickman, S., Izzy, S., Sen, P., Morsett, L., & El Khoury, J. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0242-x · Cited by 1,710 · see citing works
Neurotransmitter modulation by the gut microbiota
Strandwitz, P. (2018) · Brain Research · doi:10.1016/j.brainres.2018.03.015 · Cited by 1,527 · see citing works
Balestrino, R., & Schapira, A. H. V. (2020) · European Journal of Neurology · doi:10.1111/ene.14108 · Cited by 1,508 · see citing works
The gut-liver axis and the intersection with the microbiome
Tripathi, A., Debelius, J., Brenner, D. A., Karin, M., Loomba, R., Schnabl, B., & Knight, R. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0011-z · Cited by 1,480 · see citing works
Self-citationKim, S., Kwon, S.-H., Kam, T.-I., Panicker, N., Karuppagounder, S. S., Lee, S., Lee, J. H., Kim, W. R., Kook, M., Foss, C. A., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.05.035 · Cited by 1,397 · see citing works
The gut microbiome in neurological disorders
Cryan, J. F., O'Riordan, K. J., Sandhu, K., Peterson, V., & Dinan, T. G. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30356-4 · Cited by 1,336 · see citing works
Martin, C. R., Osadchiy, V., Kalani, A., & Mayer, E. A. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.04.003 · Cited by 1,284 · see citing works
Age and Age-Related Diseases: Role of Inflammation Triggers and Cytokines
Rea, I. M., Gibson, D. S., McGilligan, V., McNerlan, S. E., Alexander, H. D., & Ross, O. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00586 · Cited by 1,267 · see citing works
Rothhammer, V., & Quintana, F. J. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0125-8 · Cited by 1,197 · see citing works
Microglial signatures and their role in health and disease
Butovsky, O., & Weiner, H. L. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0057-5 · Cited by 1,046 · see citing works
Human Gut Microbiota from Autism Spectrum Disorder Promote Behavioral Symptoms in Mice
Sharon, G., Cruz, N. J., Kang, D.-W., Gandal, M. J., Wang, B., Kim, Y.-M., Zink, E. M., Casey, C. P., Taylor, B. C., Lane, C. J., et al. (2019) · Cell · doi:10.1016/j.cell.2019.05.004 · Cited by 1,182 · see citing works
Self-citationMicrobiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases
Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01743-1 · Cited by 1,193 · see citing works
Major depressive disorder: hypothesis, mechanism, prevention and treatment
Cui, L., Li, S., Wang, S., Wu, X., Liu, Y., Yu, W., Wang, Y., Tang, Y., Xia, M., & Li, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01738-y · Cited by 1,061 · see citing works
“241 Alterations in the gut microbiota and in fl ammatory agents have an impact on the KYN pathway, metabolism, and toxin metabolism in the periphery.”
BackgroundThe Continuum of Aging and Age-Related Diseases: Common Mechanisms but Different Rates
Franceschi, C., Garagnani, P., Morsiani, C., Conte, M., Santoro, A., Grignolio, A., Monti, D., Capri, M., & Salvioli, S. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00061 · Cited by 945 · see citing works
Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection
Thaiss, C. A., Levy, M., Grosheva, I., Zheng, D., Soffer, E., Blacher, E., Braverman, S., Tengeler, A. C., Barak, O., Elazar, M., et al. (2018) · Science · doi:10.1126/science.aar3318 · Cited by 942 · see citing works
Berer, K., Gerdes, L. A., Cekanaviciute, E., Jia, X., Xiao, L., Xia, Z., Liu, C., Klotz, L., Stauffer, U., Baranzini, S. E., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1711233114 · Cited by 933 · see citing works
Chen, Y., Xu, J., & Chen, Y. (2021) · Nutrients · doi:10.3390/nu13062099 · Cited by 917 · see citing works
Hill‐Burns, E. M., Debelius, J. W., Morton, J. T., Wissemann, W. T., Lewis, M. R., Wallen, Z. D., Peddada, S. D., Factor, S. A., Molho, E., Zabetian, C. P., et al. (2017) · Movement Disorders · doi:10.1002/mds.26942 · Cited by 874 · see citing works
Self-citationThe Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders
Socała, K., Doboszewska, U., Szopa, A., Serefko, A., Włodarczyk, M., Zielińska, A., Poleszak, E., Fichna, J., & Wlaź, P. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105840 · Cited by 857 · see citing works
Microbiota-Brain-Gut Axis and Neurodegenerative Diseases
Quigley, E. M. M. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0802-6 · Cited by 804 · see citing works
The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology
Rutsch, A., Kantsjö, J. B., & Ronchi, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.604179 · Cited by 821 · see citing works
Microbiome Influences Prenatal and Adult Microglia in a Sex-Specific Manner
Thion, M. S., Low, D., Silvin, A., Chen, J., Grisel, P., Schulte-Schrepping, J., Blecher, R., Ulas, T., Squarzoni, P., Hoeffel, G., et al. (2018) · Cell · doi:10.1016/j.cell.2017.11.042 · Cited by 779 · see citing works
van de Wouw, M., Boehme, M., Lyte, J. M., Wiley, N., Strain, C., O'Sullivan, O., Clarke, G., Stanton, C., Dinan, T. G., & Cryan, J. F. (2018) · The Journal of Physiology · doi:10.1113/jp276431 · Cited by 789 · see citing works
Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications
Pajares, M., I. Rojo, A., Manda, G., Boscá, L., & Cuadrado, A. (2020) · Cells · doi:10.3390/cells9071687 · Cited by 779 · see citing works
Sun, M.-F., Zhu, Y.-L., Zhou, Z.-L., Jia, X.-B., Xu, Y.-D., Yang, Q., Cui, C., & Shen, Y.-Q. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.02.005 · Cited by 736 · see citing works
Potential roles of gut microbiome and metabolites in modulating ALS in mice
Blacher, E., Bashiardes, S., Shapiro, H., Rothschild, D., Mor, U., Dori-Bachash, M., Kleimeyer, C., Moresi, C., Harnik, Y., Zur, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1443-5 · Cited by 700 · see citing works
Zheng, P., Zeng, B., Liu, M., Chen, J., Pan, J., Han, Y., Liu, Y., Cheng, K., Zhou, C., Wang, H., et al. (2019) · Science Advances · doi:10.1126/sciadv.aau8317 · Cited by 704 · see citing works
MahmoudianDehkordi, S., Arnold, M., Nho, K., Ahmad, S., Jia, W., Xie, G., Louie, G., Kueider‐Paisley, A., Moseley, M. A., Thompson, J. W., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.217 · Cited by 706 · see citing works
Romano, S., Savva, G. M., Bedarf, J. R., Charles, I. G., Hildebrand, F., & Narbad, A. (2021) · npj Parkinson's Disease · doi:10.1038/s41531-021-00156-z · Cited by 707 · see citing works
Function and therapeutic value of astrocytes in neurological diseases
Lee, H.-G., Wheeler, M. A., & Quintana, F. J. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00390-x · Cited by 662 · see citing works
Our gut microbiome: The evolving inner self
Kundu, P., Blacher, E., Elinav, E., & Pettersson, S. (2017) · Cell · doi:10.1016/j.cell.2017.11.024 · Cited by 633 · see citing works
Bedarf, J. R., Hildebrand, F., Coelho, L. P., Sunagawa, S., Bahram, M., Goeser, F., Bork, P., & Wüllner, U. (2017) · Genome Medicine · doi:10.1186/s13073-017-0428-y · Cited by 642 · see citing works
Kim, M.-S., Kim, Y., Choi, H., Kim, W., Park, S., Lee, D., Kim, D. K., Kim, H. J., Choi, H., Hyun, D.-W., et al. (2020) · Gut · doi:10.1136/gutjnl-2018-317431 · Cited by 614 · see citing works
Zhao, Z., Ning, J., Bao, X.-Q., Shang, M., Ma, J., Li, G., & Zhang, D. (2021) · Microbiome · doi:10.1186/s40168-021-01107-9 · Cited by 616 · see citing works
Walter, J., Armet, A. M., Finlay, B. B., & Shanahan, F. (2020) · Cell · doi:10.1016/j.cell.2019.12.025 · Cited by 596 · see citing works
Heintz‐Buschart, A., Pandey, U., Wicke, T., Sixel‐Döring, F., Janzen, A., Sittig‐Wiegand, E., Trenkwalder, C., Oertel, W. H., Mollenhauer, B., & Wilmes, P. (2018) · Movement Disorders · doi:10.1002/mds.27105 · Cited by 554 · see citing works
Britton, G. J., Contijoch, E. J., Mogno, I., Vennaro, O. H., Llewellyn, S. R., Ng, R., Li, Z., Mortha, A., Merad, M., Das, A., et al. (2019) · Immunity · doi:10.1016/j.immuni.2018.12.015 · Cited by 549 · see citing works
Zarrinpar, A., Chaix, A., Xu, Z. Z., Chang, M. W., Marotz, C. A., Saghatelian, A., Knight, R., & Panda, S. (2018) · Nature Communications · doi:10.1038/s41467-018-05336-9 · Cited by 546 · see citing works
Self-citationMicrobial regulation of organismal energy homeostasis
Cani, P. D., Van Hul, M., Lefort, C., Depommier, C., Rastelli, M., & Everard, A. (2019) · Nature Metabolism · doi:10.1038/s42255-018-0017-4 · Cited by 569 · see citing works
The Gut–Brain Axis and the Microbiome: Mechanisms and Clinical Implications
Osadchiy, V., Martin, C. R., & Mayer, E. A. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.10.002 · Cited by 555 · see citing works
The gut microbiome in human neurological disease: A review
Tremlett, H., Bauer, K. C., Appel‐Cresswell, S., Finlay, B. B., & Waubant, E. (2017) · Annals of Neurology · doi:10.1002/ana.24901 · Cited by 535 · see citing works
van Kessel, S. P., Frye, A. K., El-Gendy, A. O., Castejon, M., Keshavarzian, A., van Dijk, G., & El Aidy, S. (2019) · Nature Communications · doi:10.1038/s41467-019-08294-y · Cited by 521 · see citing works
Self-citationA gut-derived metabolite alters brain activity and anxiety behaviour in mice
Needham, B. D., Funabashi, M., Adame, M. D., Wang, Z., Boktor, J. C., Haney, J., Wu, W.-L., Rabut, C., Ladinsky, M. S., Hwang, S.-J., et al. (2022) · Nature · doi:10.1038/s41586-022-04396-8 · Cited by 489 · see citing works
Self-citationErny, D., Dokalis, N., Mezö, C., Castoldi, A., Mossad, O., Staszewski, O., Frosch, M., Villa, M., Fuchs, V., Mayer, A., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.10.010 · Cited by 478 · see citing works
Role of TLR4 in the gut-brain axis in Parkinson's disease: A translational study from men to mice
Perez-Pardo, P., Dodiya, H. B., Engen, P. A., Forsyth, C. B., Huschens, A. M., Shaikh, M., Voigt, R. M., Naqib, A., Green, S. J., Kordower, J. H., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316844 · Cited by 467 · see citing works
Self-citationRole of gut-brain axis, gut microbial composition, and probiotic intervention in Alzheimer's disease
Kesika, P., Suganthy, N., Sivamaruthi, B. S., & Chaiyasut, C. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118627 · Cited by 479 · see citing works
Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson's disease
Lin, C.-H., Chen, C.-C., Chiang, H.-L., Liou, J.-M., Chang, C.-M., Lu, T.-P., Chuang, E. Y., Tai, Y.-C., Cheng, C., Lin, H.-Y., et al. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1528-y · Cited by 469 · see citing works
Microbiome–microglia connections via the gut–brain axis
Abdel-Haq, R., Schlachetzki, J. C. M., Glass, C. K., & Mazmanian, S. K. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20180794 · Cited by 471 · see citing works
“Second, dysbiosis is observed in several neurological conditions in which microglial dysfunction is thought to be a contributing factor to disease development, including ASD and PD (Table 1; Hsiao et al., 2013; Sampson et al., 2016).”
BackgroundSelf-citationParkinson disease and the immune system - Associations, mechanisms and therapeutics
Tan, E.-K., Chao, Y.-X., West, A., Chan, L.-L., Poewe, W., & Jankovic, J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0344-4 · Cited by 457 · see citing works
Interconnected Microphysiological Systems for Quantitative Biology and Pharmacology Studies
Edington, C. D., Chen, W. L. K., Geishecker, E., Kassis, T., Soenksen, L. R., Bhushan, B. M., Freake, D., Kirschner, J., Maass, C., Tsamandouras, N., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22749-0 · Cited by 487 · see citing works
The endotoxin hypothesis of neurodegeneration
Brown, G. C. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1564-7 · Cited by 457 · see citing works
Gut microbiota: A player in aging and a target for anti-aging intervention
Vaiserman, A. M., Koliada, A. K., & Marotta, F. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.01.001 · Cited by 465 · see citing works
Microbiota-derived metabolites as drivers of gut–brain communication
Ahmed, H., Leyrolle, Q., Koistinen, V., Kärkkäinen, O., Layé, S., Delzenne, N., & Hanhineva, K. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2102878 · Cited by 462 · see citing works
Dysbiosis of gut microbiota and microbial metabolites in Parkinson's disease
Sun, M.-F., & Shen, Y.-Q. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.04.004 · Cited by 445 · see citing works
Diet and the Microbiota–Gut–Brain Axis: Sowing the Seeds of Good Mental Health
Berding, K., Vlckova, K., Marx, W., Schellekens, H., Stanton, C., Clarke, G., Jacka, F., Dinan, T. G., & Cryan, J. F. (2021) · Advances in Nutrition · doi:10.1093/advances/nmaa181 · Cited by 451 · see citing works
Altered Gut Microbiota in a Mouse Model of Alzheimer’s Disease
Zhang, L., Wang, Y., Xiayu, X., Shi, C., Chen, W., Song, N., Fu, X., Zhou, R., Xu, Y.-F., Huang, L., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170020 · Cited by 449 · see citing works
Metagenome-wide association of gut microbiome features for schizophrenia
Zhu, F., Ju, Y., Wang, W., Wang, Q., Guo, R., Ma, Q., Sun, Q., Fan, Y., Xie, Y., Yang, Z., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15457-9 · Cited by 409 · see citing works
A gut bacterial amyloid promotes α-synuclein aggregation and motor impairment in mice
Sampson, T. R., Challis, C., Jain, N., Moiseyenko, A., Ladinsky, M. S., Shastri, G. G., Thron, T., Needham, B. D., Horvath, I., Debelius, J. W., et al. (2020) · eLife · doi:10.7554/elife.53111 · Cited by 439 · see citing works
Self-citationRegulation of life span by the gut microbiota in the short-lived African turquoise killifish
Smith, P., Willemsen, D., Popkes, M., Metge, F., Gandiwa, E., Reichard, M., & Valenzano, D. R. (2017) · eLife · doi:10.7554/elife.27014 · Cited by 423 · see citing works
The gut microbiota and healthy aging: A mini-review
Kim, S., & Jazwinski, S. M. (2018) · Gerontology · doi:10.1159/000490615 · Cited by 427 · see citing works
Alteration of the fecal microbiota in Chinese patients with Parkinson’s disease
Qian, Y., Yang, X., Xu, S., Wu, C., Song, Y., Qin, N., Chen, S.-D., & Xiao, Q. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.02.016 · Cited by 409 · see citing works
Gut-seeded α-synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice
Challis, C., Hori, A., Sampson, T. R., Yoo, B. B., Challis, R. C., Hamilton, A. M., Mazmanian, S. K., Volpicelli-Daley, L. A., & Gradinaru, V. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0589-7 · Cited by 405 · see citing works
Self-citationGut Microbiota: An Integral Moderator in Health and Disease
Feng, Q., Chen, W.-D., & Wang, Y.-D. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00151 · Cited by 407 · see citing works
Peter, I., Dubinsky, M., Bressman, S., Park, A., Lu, C., Chen, N., & Wang, A. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0605 · Cited by 386 · see citing works
Fecal Microbiota Transplantation in Neurological Disorders
Vendrik, K. E. W., Ooijevaar, R. E., de Jong, P. R. C., Laman, J. D., van Oosten, B. W., van Hilten, J. J., Ducarmon, Q. R., Keller, J. J., Kuijper, E. J., & Contarino, M. F. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00098 · Cited by 413 · see citing works
Microbiota-Gut-Brain Axis: New Therapeutic Opportunities
Long-Smith, C., O'Riordan, K. J., Clarke, G., Stanton, C., Dinan, T. G., & Cryan, J. F. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023628 · Cited by 419 · see citing works
Signalling cognition: The gut microbiota and hypothalamic-pituitary-adrenal axis
Rusch, J. A., Layden, B. T., & Dugas, L. R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1130689 · Cited by 415 · see citing works
(Dis)Trust your gut: the gut microbiome in age-related inflammation, health, and disease
Buford, T. W. (2017) · Microbiome · doi:10.1186/s40168-017-0296-0 · Cited by 409 · see citing works
Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism
Barichella, M., Severgnini, M., Cilia, R., Cassani, E., Bolliri, C., Caronni, S., Ferri, V., Cancello, R., Ceccarani, C., Faierman, S., et al. (2019) · Movement Disorders · doi:10.1002/mds.27581 · Cited by 393 · see citing works
The microbiome–gut–brain axis in Parkinson disease — from basic research to the clinic
Tan, A. H., Lim, S. Y., & Lang, A. E. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00681-2 · Cited by 392 · see citing works
Relationship between the gut microbiome and brain function
Mohajeri, M. H., La Fata, G., Steinert, R. E., & Weber, P. (2018) · Nutrition Reviews · doi:10.1093/nutrit/nuy009 · Cited by 376 · see citing works
The Microbiome and Human Biology
Knight, R., Callewaert, C., Marotz, C., Hyde, E. R., Debelius, J. W., McDonald, D., & Sogin, M. L. (2017) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083115-022438 · Cited by 373 · see citing works
Self-citationGut microbial molecules in behavioural and neurodegenerative conditions
Needham, B. D., Kaddurah-Daouk, R., & Mazmanian, S. K. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-020-00381-0 · Cited by 379 · see citing works
Self-citation<scp>Meta‐Analysis</scp> of Gut Dysbiosis in Parkinson's Disease
Nishiwaki, H., Ito, M., Ishida, T., Hamaguchi, T., Maeda, T., Kashihara, K., Tsuboi, Y., Ueyama, J., Shimamura, T., Mori, H., et al. (2020) · Movement Disorders · doi:10.1002/mds.28119 · Cited by 370 · see citing works
Microbiome-Gut-Brain Axis and Toll-Like Receptors in Parkinson’s Disease
Caputi, V., & Giron, M. C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061689 · Cited by 338 · see citing works
Microbiota-derived short chain fatty acids modulate microglia and promote Aβ plaque deposition
Colombo, A. V., Sadler, R. K., Llovera, G., Singh, V., Roth, S., Heindl, S., Sebastian Monasor, L., Verhoeven, A., Peters, F., Parhizkar, S., et al. (2021) · eLife · doi:10.7554/elife.59826 · Cited by 354 · see citing works
Metagenomics of Parkinson’s disease implicates the gut microbiome in multiple disease mechanisms
Wallen, Z. D., Demirkan, A., Twa, G., Cohen, G., Dean, M. N., Standaert, D. G., Sampson, T. R., & Payami, H. (2022) · Nature Communications · doi:10.1038/s41467-022-34667-x · Cited by 346 · see citing works
Self-citationC9orf72 suppresses systemic and neural inflammation induced by gut bacteria
Burberry, A., Wells, M. F., Limone, F., Couto, A., Smith, K. S., Keaney, J., Gillet, G., van Gastel, N., Wang, J.-Y., Pietilainen, O., et al. (2020) · Nature · doi:10.1038/s41586-020-2288-7 · Cited by 314 · see citing works
Gut-licensed IFNγ+ NK cells drive LAMP1+TRAIL+ anti-inflammatory astrocytes
Sanmarco, L. M., Wheeler, M. A., Gutiérrez-Vázquez, C., Polonio, C. M., Linnerbauer, M., Pinho-Ribeiro, F. A., Li, Z., Giovannoni, F., Batterman, K. V., Scalisi, G., et al. (2021) · Nature · doi:10.1038/s41586-020-03116-4 · Cited by 331 · see citing works
16S rRNA Next Generation Sequencing Analysis Shows Bacteria in Alzheimer’s Post-Mortem Brain
Emery, D. C., Shoemark, D. K., Batstone, T. E., Waterfall, C. M., Coghill, J. A., Cerajewska, T. L., Davies, M., West, N. X., & Allen, S. J. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00195 · Cited by 317 · see citing works
Wang, Y., Tong, Q., Ma, S.-R., Zhao, Z.-X., Pan, L.-B., Cong, L., Han, P., Peng, R., Yu, H., Lin, Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00456-5 · Cited by 319 · see citing works
Heiss, C. N., & Olofsson, L. E. (2019) · Journal of Neuroendocrinology · doi:10.1111/jne.12684 · Cited by 304 · see citing works
Xu, M., Xu, X., Li, J., & Li, F. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00473 · Cited by 309 · see citing works
Sex-specific effects of microbiome perturbations on cerebral Aβ amyloidosis and microglia phenotypes
Dodiya, H. B., Kuntz, T., Shaik, S. M., Baufeld, C., Leibowitz, J., Zhang, X., Gottel, N., Zhang, X., Butovsky, O., Gilbert, J. A., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20182386 · Cited by 288 · see citing works
Li, J.-M., Yu, R., Zhang, L.-P., Wen, S.-Y., Wang, S.-J., Zhang, X.-Y., Xu, Q., & Kong, L.-D. (2019) · Microbiome · doi:10.1186/s40168-019-0713-7 · Cited by 300 · see citing works
Minter, M. R., Hinterleitner, R., Meisel, M., Zhang, C., Leone, V., Zhang, X., Oyler-Castrillo, P., Zhang, X., Musch, M. W., Shen, X., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11047-w · Cited by 292 · see citing works
The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options
Wang, Q., Luo, Y., Ray Chaudhuri, K., Reynolds, R., Tan, E.-K., & Pettersson, S. (2021) · Brain · doi:10.1093/brain/awab156 · Cited by 281 · see citing works
The gut microbiome in Alzheimer’s disease: what we know and what remains to be explored
Chandra, S., Sisodia, S. S., & Vassar, R. J. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00595-7 · Cited by 278 · see citing works
Pellegrini, C., Antonioli, L., Colucci, R., Blandizzi, C., & Fornai, M. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1856-5 · Cited by 270 · see citing works
Unhealthy gut, unhealthy brain: The role of the intestinal microbiota in neurodegenerative diseases
Spielman, L. J., Gibson, D. L., & Klegeris, A. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.08.005 · Cited by 266 · see citing works
Sun, J., Li, H., Jin, Y., Yu, J., Mao, S., Su, K.-P., Ling, Z., & Liu, J. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.10.014 · Cited by 264 · see citing works
Gut microbiota in patients with Parkinson's disease in southern China
Lin, A., Zheng, W., He, Y., Tang, W., Wei, X., He, R., Huang, W., Su, Y., Huang, Y., Zhou, H., et al. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.05.007 · Cited by 253 · see citing works
Chen, S.-J., Chen, C.-C., Liao, H.-Y., Lin, Y.-T., Wu, Y.-W., Liou, J.-M., Wu, M.-S., Kuo, C.-H., & Lin, C.-H. (2022) · Neurology · doi:10.1212/wnl.0000000000013225 · Cited by 269 · see citing works
Seo, D.-O., O’Donnell, D., Jain, N., Ulrich, J. D., Herz, J., Li, Y., Lemieux, M., Cheng, J., Hu, H., Serrano, J. R., et al. (2023) · Science · doi:10.1126/science.add1236 · Cited by 254 · see citing works
- Authors
- Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., Chesselet, M.-F., Keshavarzian, A., Shannon, K. M., Krajmalnik-Brown, R., Wittung-Stafshede, P., Knight, R., & Mazmanian, S. K.
- Affiliations
- California Institute of Technology (US)
- University of California San Diego (US)
- Arizona State University (US)
- Chalmers University of Technology (SE)
- Rush University Medical Center (US)
- Corresponding author
- Sampson, Timothy R.
- Mazmanian, Sarkis K.
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 167
- Issue
- 6
- Pages
- 1469-1480.e12
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC5718049
- OpenAlex
- W2558041282
- Cited by
- 3,622
- References
- 75
- Citations by year
- 2026: 363 · 2025: 414 · 2024: 421 · 2023: 410 · 2022: 455 · 2021: 450 · 2020: 385 · 2019: 300 · 2018: 247 · 2017: 171 · 2016: 5
- FWCI
- 181.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Chalmers Research (Chalmers University of Technology) (submittedVersion)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion)
- HAL (submittedVersion)
- PUB – Publications at Bielefeld University (Bielefeld University) (submittedVersion)
- Chalmers Publication Library (Chalmers University of Technology) (submittedVersion)
- Funders
- Caltech Beckman Institute
- Arnold and Mabel Beckman Foundation
- Larry L. Hillblom Foundation
- Knut and Alice Wallenberg Foundation
- Swedish Research Council
- Mrs. and Mr. Larry Field
- Heritage Medical Research Institute
- NIH (NS085910)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- gut microbiota, Parkinson's disease, alpha-synuclein, synucleinopathies, motor impairment, neuroinflammation, microglial activation, microbiota transplantation, germ-free mice, antibiotic therapy, microbial metabolites, gut-brain axis, neurodegeneration
- MeSH terms
- Gastrointestinal Microbiome, Animals, Brain, Fatty Acids, Humans, Inflammation, Parkinson Disease, Microglia, Gastrointestinal Tract, Mice, alpha-Synuclein, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
